Pharmaceuticals · Pharmaceuticals: Major · NSE: NECLIFE · data 2026-10-30
Nectar Lifesciences Ltd.
In plain words
Price: 54.5% below its 52-week high of ₹22.4.
Delivery: 76.9% of traded shares were kept for delivery over the last 10 sessions, against 74.8% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹7 cr |
| Net profit (last 12 months) | ₹-245 cr |
| Sales growth, 3 years (yearly) | -90.6% |
| Profit growth, 3 years (yearly) | — |
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 76.4% over the last 20 sessions vs 74.2% in the 40 before (1.03x); shares delivered per day 0.7x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Nectar Lifesciences Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is the 52-week high and low of Nectar Lifesciences Ltd.?
The 52-week high is ₹22.4 and the 52-week low is ₹9.3.
Similar companies
Ambalal Sarabhai Enterprises Limited (AMBALALSA) · Accretion Pharmaceuticals Ltd. (ACCPL) · Brooks Laboratories Limited (BROOKS) · Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NECLIFE in NSE Scanner →